{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:35:01Z","timestamp":1753889701041,"version":"3.41.2"},"reference-count":43,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>WHO indicates that diabetes will become the 7th leading reason for\ndeath by 2030. The physiopathology of dysfunctioning is associated with obesity, weight gain\nand predominantly insulin resistance in insulin-sensitive cells and continuous deterioration of\npancreatic beta cell function. Imeglimin is an investigational novel oral anti-diabetic drug.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The motive of the review is to comprehensively explore the chemistry, biological\nand analytical analysis of the Imeglimin hydrochloride<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>To enhance the understanding, a systematic review was conducted by forming a database of relevant existing studies from electronic resources like Web of Science, ScienceDirect\nand PubMed. The methodology is reflected in the PRISMA design.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result:<\/jats:title>\n<jats:p>The drug was approved in the year 2021 for therapeutic purposes in Japan. It is the novel\nand first approved drug for this type of Anti-diabetic treatment. It is a small molecular drug\nwhose molecular weight is 191.6 grams per mole utilized for oral administration. Imeglimin is\nthought to have both activities, as the amount of glucose is dependent on insulin secretory impact and insulin sensitivity is increased.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Therapeutic, pharmacological, and analytical considerations for the novel drug\nImeglimin hydrochloride are discussed in this review.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115733998260331231009104035","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T11:36:54Z","timestamp":1697715414000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and Biological Properties of Imeglimin Hydrochlo ride,\nA Novel Antidiabetic Agent: A Systematic Review"],"prefix":"10.2174","volume":"20","author":[{"given":"Jasira","family":"Sultan","sequence":"first","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy &amp; Technology Management, SVKM's NMIMS Deemed to be University,\nVile Parle West, Mumbai, Maharashtra 400056, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-6579","authenticated-orcid":true,"given":"Nikhil","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy &amp; Technology Management, SVKM's NMIMS Deemed to be University,\nVile Parle West, Mumbai, Maharashtra 400056, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Sharma","sequence":"additional","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy &amp; Technology Management, SVKM's NMIMS Deemed to be University,\nVile Parle West, Mumbai, Maharashtra 400056, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.dsx.2018.10.008","volume":"13","author":"Tan S.Y.","year":"2019","unstructured":"Tan S.Y.; Mei Wong J.L.; Sim Y.J.; Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr  2019,13(1),364-372","journal-title":"Diabetes Metab Syndr"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1517\/14656566.2010.506479","volume":"11","author":"Verrotti A.","year":"2010","unstructured":"Verrotti A.; Chiuri R.M.; Blasetti A.; Mohn A.; Chiarelli F.; Treatment options for paediatric diabetes. Expert Opin Pharmacother  2010,11(15),2483-2495","journal-title":"Expert Opin Pharmacother"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jama.2020.17738","volume":"325","year":"2021","unstructured":"JAMA The Prevention of Diabetes Mellitus 2021,325(2),190","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.2174\/138955751514151006154616","volume":"15","author":"Sen S.","year":"2015","unstructured":"Sen S.; Chakraborty R.; EDITORIAL (Thematic issue: Treatment and diagnosis of diabetes mellitus and its complication: Advanced approaches). Mini Rev Med Chem  2015,15(14),1132-1133","journal-title":"Mini Rev Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/db08-1611","volume":"58","author":"Meier J.J.","year":"2009","unstructured":"Meier J.J.; Menge B.A.; Breuer T.G.K.; Functional assessment of pancreatic beta-cell area in humans. Diabetes  2009,58(7),1595-1603","journal-title":"Diabetes"},{"journal-title":"Global Report on Diabetes","year":"2016","key":"ref=6","unstructured":"Global Report on Diabetes World Health Organization Available from:  http:\/\/www.who.int\/about\/licensing\/%5Cn\n http:\/\/apps.who.int\/iris\/bitstream\/10665\/204871\/1\/9789241565257_eng.pdf\n2016"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"Cho N.H.","year":"2018","unstructured":"Cho N.H.; Shaw J.E.; Karuranga S.; IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract  2018,138,271-281","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2337\/db16-0806","volume":"66","author":"Skyler J.S.","year":"2017","unstructured":"Skyler J.S.; Bakris G.L.; Bonifacio E.; Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes  2017,66(2),241-255","journal-title":"Diabetes"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.17925\/EE.2021.17.2.88","volume":"17","author":"Doupis J.","year":"2021","unstructured":"Doupis J.; Baris N.; Avramidis K.; Imeglimin: A new promising and effective weapon in the treatment of type 2 diabetes. TouchREVIEWS Endocrinol  2021,17,88-91","journal-title":"TouchREVIEWS Endocrinol"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1880420\/v1","author":"Hozumi K.","year":"2022","unstructured":"Hozumi K.; Sugawara K.; Ishihara T.; Ishihara N.; Ogawa W.; Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes Research Square  2022","journal-title":"Research Square"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.2337\/db14-1220","volume":"64","author":"Vial G.","year":"2015","unstructured":"Vial G.; Chauvin M.A.; Bendridi N.; Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes  2015,64(6),2254-2264","journal-title":"Diabetes"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s40262-020-00886-y","volume":"59","author":"Fouqueray P.","year":"2020","unstructured":"Fouqueray P.; Perrimond-Dauchy S.; Bolze S.; Imeglimin does not induce clinically relevant pharmacokinetic interactions when combined with either metformin or sitagliptin in healthy subjects. Clin Pharmacokinet  2020,59(10),1261-1271","journal-title":"Clin Pharmacokinet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/S0140-6736(08)60768-0","volume":"371","author":"Mazzone T.","year":"2008","unstructured":"Mazzone T.; Chait A.; Plutzky J.; Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet  2008,371(9626),1800-1809","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ddr.21636","volume":"81","author":"Yendapally R.","year":"2020","unstructured":"Yendapally R.; Sikazwe D.; Kim S.S.; A review of phenformin, metformin, and imeglimin. Drug Dev Res  2020,81(4),390-401","journal-title":"Drug Dev Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/cts.13221","volume":"15","author":"Tomita Y.","year":"2022","unstructured":"Tomita Y.; Hansson E.; Mazuir F.; Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes. Clin Transl Sci  2022,15(4),1014-1026","journal-title":"Clin Transl Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5603\/EP.a2022.0014","volume":"73","author":"Nowak M.","year":"2022","unstructured":"Nowak M.; Grzeszczak W.; Imeglimin: A new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes. Endokrynol Pol  2022,73(2),361-370","journal-title":"Endokrynol Pol"},{"key":"ref=17","first-page":"8","volume":"33","author":"Sanjay K.","year":"2022","unstructured":"Sanjay K.; Bhattacharya saptarshi SS. Imeglimin : Find Place Mod Diabetes  2022,33,8-11","journal-title":"Find Place Mod Diabetes"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"103331","DOI":"10.1016\/j.drudis.2022.07.016","volume":"27","author":"Zhang X.","year":"2022","unstructured":"Zhang X.; Kupczyk E.; Schmitt-Kopplin P.; Mueller C.; Current and future approaches for in vitro hit discovery in diabetes mellitus. Drug Discov Today  2022,27(10),103331","journal-title":"Drug Discov Today"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jdi.13669","volume":"13","author":"Funazaki S.","year":"2022","unstructured":"Funazaki S.; Yoshida M.; Yamada H.; A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway. J Diabetes Investig  2022,13(1),34-41","journal-title":"J Diabetes Investig"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/dom.12452","volume":"17","author":"Pacini G.","year":"2015","unstructured":"Pacini G.; Mari A.; Fouqueray P.; Bolze S.; Roden M.; Imeglimin increases glucose-dependent insulin secretion and improves \u03b2-cell function in patients with type 2 diabetes. Diabetes Obes Metab  2015,17(6),541-545","journal-title":"Diabetes Obes Metab"},{"key":"ref=21","author":"Julie D.","year":"2019","unstructured":"Julie D.;  Clinical evidence to support the safety and efficacy of imeglimin in various populations of patients with type 2 diabetes  Available from:  https:\/\/www.easd.org\/mediacentre\/home.html#!resources\/clinical-evidence-to-support-thesafety-and-efficacy-of-imeglimin-in-various-populations-ofpatients-with-type-2-diabetes2019","journal-title":"Clinical evidence to support the safety and efficacy of imeglimin in various populations of patients with type 2 diabetes"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40262-020-00948-1","volume":"60","author":"Chevalier C.","year":"2021","unstructured":"Chevalier C.; Dubourg J.; Bolze S.; Fouqueray P.; Pharmacokinetics of imeglimin in subjects with moderate hepatic impairment. Clin Pharmacokinet  2021,60(4),485-490","journal-title":"Clin Pharmacokinet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40265-021-01589-9","volume":"81","author":"Lamb Y.N.","year":"2021","unstructured":"Lamb Y.N.; Imeglimin hydrochloride: First approval. Drugs  2021,81(14),1683-1690","journal-title":"Drugs"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40261-022-01181-3","volume":"42","author":"Fouqueray P.","year":"2022","unstructured":"Fouqueray P.; Chevalier C.; Bolze S.; Pharmacokinetics of imeglimin in Caucasian and Japanese healthy subjects. Clin Drug Investig  2022,42(9),721-732","journal-title":"Clin Drug Investig"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/dom.14277","volume":"23","author":"Hallakou-Bozec S.","year":"2021","unstructured":"Hallakou-Bozec S.; Vial G.; Kergoat M.; Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab  2021,23(3),664-673","journal-title":"Diabetes Obes Metab"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14656566.2020.1729123","volume":"21","author":"Johansson K.S.","year":"2020","unstructured":"Johansson K.S.; Br\u00f8nden A.; Knop F.K.; Christensen M.B.; Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. Expert Opin Pharmacother  2020,21(8),871-882","journal-title":"Expert Opin Pharmacother"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40265-020-01434-5","volume":"81","author":"Konkwo C.","year":"2021","unstructured":"Konkwo C.; Perry R.J.; Imeglimin: Current development and future potential in type 2 diabetes. Drugs  2021,81(2),185-190","journal-title":"Drugs"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"e00193","DOI":"10.1002\/edm2.193","volume":"4","author":"Hallakou-Bozec S.","year":"2020","unstructured":"Hallakou-Bozec S.; Kergoat M.; Moller D.E.; Bolze S.; Imeglimin preserves islet \u03b2-cell mass in type 2 diabetic ZDF rats. Endocrinol Diabetes Metab  2020,4(2),e00193","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"102323","DOI":"10.1016\/j.dsx.2021.102323","volume":"15","author":"Abdelhaleem I.A.","year":"2021","unstructured":"Abdelhaleem I.A.; Salamah H.M.; Alsabbagh F.A.; Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Diabetes Metab Syndr  2021,15(6),102323","journal-title":"Diabetes Metab Syndr"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e0241651","DOI":"10.1371\/journal.pone.0241651","volume":"16","author":"Hallakou-Bozec S.","year":"2021","unstructured":"Hallakou-Bozec S.; Kergoat M.; Fouqueray P.; Bolze S.; Moller D.E.; Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS One  2021,16(2),e0241651","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/dom.14285","volume":"23","author":"Dubourg J.","year":"2021","unstructured":"Dubourg J.; Ueki K.; Grouin J.M.; Fouqueray P.; Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Diabetes Obes Metab  2021,23(3),800-810","journal-title":"Diabetes Obes Metab"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.2337\/dc13-2349","volume":"37","author":"Fouqueray P.","year":"2014","unstructured":"Fouqueray P.; Pirags V.; Diamant M.; The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care  2014,37(7),1924-1930","journal-title":"Diabetes Care"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.15277\/bjd.2020.247","volume":"20","author":"Crabtree T.S.J.","year":"2020","unstructured":"Crabtree T.S.J.; DeFronzo R.A.; Ryder R.E.J.; Bailey C.J.; Imeglimin, a novel, first in-class, blood glucose-lowering agent: A systematic review and meta-analysis of clinical evidence. British J Diabetes  2020,20(1),28-31","journal-title":"British J Diabetes"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"Page M.J.","year":"2021","unstructured":"Page M.J.; McKenzie J.E.; Bossuyt P.M.; The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ  2021,372,n71","journal-title":"BMJ"},{"year":"2023","key":"ref=35","unstructured":"National Center for Biotechnology Information Available from:  https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Imeglimin-hydrochloride2023"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1463-1326.2012.01611.x","volume":"14","author":"Pirags V.","year":"2012","unstructured":"Pirags V.; Lebovitz H.; Fouqueray P.; Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab  2012,14(9),852-858","journal-title":"Diabetes Obes Metab"},{"year":"2021","key":"ref=37","unstructured":"New drug approvals. Meglimin hydrochloride Available from:  https:\/\/newdrugapprovals.org\/2021\/06\/30\/23943\/2021"},{"key":"ref=38","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6156.1000126","volume":"2","author":"Fouqueray P.","year":"2011","unstructured":"Fouqueray P.; Leverve X.; Fontaine E.; Baqui\u00e9 M.; Wollheim C.; Imeglimin - A new oral anti-diabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab  2011,2(4)","journal-title":"J Diabetes Metab"},{"journal-title":"Twymeeg Tablets Sumitomo Dainippon Pharma Co, Ltdreview report","year":"2019","key":"ref=39","unstructured":"Pharmaceutical Safety and Environmental Health Bureau Ministry of Health L and W 2021. Twymeeg Tablets Sumitomo Dainippon Pharma Co, Ltdreview report Pharmaceutical Evaluation Division 2019"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4155\/bio.12.44","volume":"4","author":"Smith G.","year":"2012","unstructured":"Smith G.; European Medicines Agency guideline on bioanalytical method validation: What more is there to say? Bioanalysis  2012,4(8),865-868","journal-title":"Bioanalysis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1124\/dmd.120.000154","volume":"48","author":"Cl\u00e9mence C.","year":"2020","unstructured":"Cl\u00e9mence C.; Fouqueray P.; S\u00e9bastien B.; In vitro investigation, pharmacokinetics, and disposition of imeglimin, a novel oral antidiabetic drug, in preclinical species and humans. Drug Metab Dispos  2020,48(12),1330-1346","journal-title":"Drug Metab Dispos"},{"year":"2016","author":"Fouqueray P.","key":"ref=42","unstructured":"Fouqueray P.; Hallakou-Bozec S.; Bolze S.L.H.; Imeglimin improves vascular dysfunction in type 2 diabetes animal models.  Availabke from:  https:\/\/www.easd.org\/mediacentre\/home.html#!resources\/imeglimin-improves-vasculardysfunction-in-type-2-diabetes-animal-models2016"},{"year":"2020","key":"ref=43","unstructured":"Poxel and sumitomo dainippon pharma announce positive top-line results for imeglimin phase 3 trial ( TIMES 1 ) in Japan for the treatment of type 2 diabetes.  Available from:  https:\/\/www.poxelpharma.com\/en_us\/investors\/news-events\/press-releases\/detail\/117\/poxel-and-sumitomo-dainippon-pharma-announce-positive2020"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733998260331231009104035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/222286\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733998260331231009104035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T12:04:28Z","timestamp":1712232268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/222286\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115733998260331231009104035","relation":{},"ISSN":["1573-3998"],"issn-type":[{"type":"print","value":"1573-3998"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e171023222286"}}